Abstract:Since the U.S. Food and Drug Administration (FDA) granted emergency use authorization for two mRNA vaccines against SARS-CoV-2, mRNA-based technology has attracted broad attention from the scientific community to investors. When delivered intracellularly, mRNA has the ability to produce various therapeutic proteins, enabling the treatment of a variety of illnesses, including but not limited to infectious diseases, cancers, and genetic diseases. Accordingly, mRNA holds significant therapeutic potential and provides a promising means to target historically hard-to-treat diseases. Current clinical efforts harnessing mRNA-based technology are focused on vaccination, cancer immunotherapy, protein replacement therapy, and genome editing. The clinical translation of mRNA-based technology has been made possible by leveraging nanoparticle delivery methods. However, the application of mRNA for therapeutic purposes is still challenged by the need for specific, efficient, and safe delivery systems.This Account highlights key advances in designing and developing combinatorial synthetic lipid nanoparticles (LNPs) with distinct chemical structures and properties for in vitro and in vivo intracellular mRNA delivery. LNPs represent the most advanced nonviral nanoparticle delivery systems that have been extensively investigated for nucleic acid delivery. The aforementioned COVID-19 mRNA vaccines and one LNP-based small interfering RNA (siRNA) drug (ONPATTRO) have received clinical approval from the FDA, highlighting the success of synthetic ionizable lipids for in vivo nucleic acid delivery. In this Account, we first summarize the research efforts from our group on the development of bioreducible and biodegradable LNPs by leveraging the combinatorial chemistry strategy, such as the Michael addition reaction, which allows us to easily generate a large set of lipidoids with diverse chemical structures. Next, we discuss the utilization of a library screening strategy to identify optimal LNPs for targeted mRNA delivery and showcase the applications of the optimized LNPs in cell engineering and genome editing. Finally, we outline key challenges to the clinical translation of mRNA-based therapies and propose an outlook for future directions of the chemical design and optimization of LNPs to improve the safety and specificity of mRNA drugs. We hope this Account provides insight into the rational design of LNPs for facilitating the development of mRNA therapeutics, a transformative technology that promises to revolutionize future medicine.

Enzyme-Catalyzed One-Step Synthesis of Ionizable Cationic Lipids for Lipid Nanoparticle-Based mRNA COVID-19 Vaccines

Dual Ethanolamine Head Groups in Ionizable Lipids Facilitate Phospholipid-free Stable Nanoparticle Formulation for Augmented and Safer mRNA Delivery

A cationic lipid with advanced membrane fusion performance for pDNA and mRNA delivery

Lipid-Polymer Hybrid "Particle-in-Particle" Nanostructure Gene Delivery Platform Explored for Lyophilizable DNA and mRNA COVID-19 Vaccines

Lipid Nanoparticles: A Novel Gene Delivery Technique for Clinical Application

Combinatorial design of ionizable lipid nanoparticles for muscle-selective mRNA delivery with minimized off-target effects

Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing

Paracyclophane-based ionizable lipids for efficient mRNA delivery in vivo

Novel Ionizable Lipid Nanoparticles for SARS‐CoV‐2 Omicron mRNA Delivery

Fabrication of mRNA encapsulated Lipid nanoparticles using State-of-the-art SMART-MaGIC Technology and transfection in vitro

Silicon Ether Ionizable Lipids Enable Potent mRNA Lipid Nanoparticles with Rapid Tissue Clearance

Fabrication of mRNA encapsulated lipid nanoparticles using state of the art SMART-MaGIC technology and transfection in vitro

Molecular Dynamics Simulation of Lipid Nanoparticles Encapsulating mRNA

High-throughput synthesis and optimization of ionizable lipids through A3 coupling for efficient mRNA delivery

Ionizable Lipids from Click Reactions for Lipid Nanoparticle Assembling and Mrna Delivery

A Basic Method for Formulating mRNA-Lipid Nanoparticle Vaccines in the Lab

An overview of lipid constituents in lipid nanoparticle mRNA delivery systems

Screening Libraries to Discover Molecular Design Principles for the Targeted Delivery of mRNA with One-Component Ionizable Amphiphilic Janus Dendrimers Derived from Plant Phenolic Acids

Development of a high-throughput platform for screening lipid nanoparticles for mRNA delivery.

Understanding structure activity relationships of Good HEPES lipids for lipid nanoparticle mRNA vaccine applications

A Facile Method to Prepare Non-Cationic Mrna Lipid-Nanoparticles Based on Frame Guided Assembly Strategy